Initial results were presented from the Phase III Letrozole/Fulvestrant and Avastin (LEA) trial of the angiogenesis inhibitor bevacizumab in combination with endocrine therapy as a first line therapy for postmenopausal women with hormone receptor positive breast cancer. The gene discussed is NR4A1; the disease is breast carcinoma.